QCM
ARCT icon

Quantinno Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Quantinno Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$577K Buy
85,875
+14,522
+20% +$114K ﹤0.01% 2905
2026
Q1 		$551K Buy
71,353
+19,230
+37% +$140K ﹤0.01% 2646
2025
Q4 		$320K Buy
+52,123
New +$563K ﹤0.01% 2787

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Quantinno Capital Management's ARCT Position: Q2 2026 in Review

Quantinno Capital Management increased its Arcturus Therapeutics (ARCT) stake by 20% in Q2 2026, buying an estimated $114K and bringing the position to 85,875 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #2905.

Quantinno Capital Management first reported a position in ARCT in Q4 2025 and has held it in 3 quarters since. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Quantinno Capital Management held 85,875 shares of Arcturus Therapeutics worth $577K as of Q2 2026.
  • Quantinno Capital Management bought 14,522 Arcturus Therapeutics shares in Q2 2026, an estimated $114K.
  • Arcturus Therapeutics made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2905 holding.
  • Quantinno Capital Management first reported a position in Arcturus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.